Macrophage-Targeted Therapeutics for Metabolic Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Macrophages are cells of the innate immune system that are resident in all tissues, including metabolic organs such as the liver and adipose tissue. Because of their phenotypic flexibility, they play beneficial roles in tissue homeostasis, but they also contribute to the progression of metabolic disease. Thus, they are ideal therapeutic targets for diseases such as insulin resistance, non-alcoholic fatty liver disease, and atherosclerosis. Recently, discoveries in the area of drug delivery have facilitated phenotype-specific targeting of macrophages. In this review, we discuss advances in potential therapeutics for metabolic diseases via macrophage-specific delivery. We highlight micro- and nano-particles, liposomes, and oligopeptide complexes, and how they can be used to alter macrophage phenotype for a more metabolically favorable tissue environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Their roles in autoimmune and inflammatory diseases are obvious; however, more recently, their contributions to cancer [1], cardiovascular disease [2, 3], and diabetes [4–6], have also been elucidated.”
BackgroundProtective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523 · cited 1×
“The encapsulation design allows for drug protection and stabilization; one method of which is PEGylation, which increases circulation time [68].”
MethodMicroglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999
Adipose tissue remodeling and obesity
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941
Brown, G. D., & Gordon, S. (2001) · Nature · doi:10.1038/35092620 · Cited by 1,579
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Adapting to obesity with adipose tissue inflammation
Reilly, S. M., & Saltiel, A. R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.90 · Cited by 1,204
Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.-L., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2277 · Cited by 1,164
Macrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121 · cited 1×
“This lipid accumulation results in foamy macrophages that are highly inflammatory and that also send chemotactic signals to recruit additional monocytes, exacerbating the lipid-enriched inflammatory milieu [44].”
BackgroundAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Phagocytosis: An Immunobiologic Process
Gordon, S. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.026 · Cited by 902
Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J. L., Hugol, D., Coussieu, C., Basdevant, A., Hen, A. B., Bedossa, P., et al. (2006) · Diabetes · doi:10.2337/db06-0133 · Cited by 607
From Blood Monocytes to Adipose Tissue-Resident Macrophages
Curat, C. A., Miranville, A., Sengenès, C., Diehl, M., Tonus, C., Busse, R., & Bouloumié, A. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1285 · Cited by 600
Kadl, A., Meher, A. K., Sharma, P. R., Lee, M. Y., Doran, A. C., Johnstone, S. R., Elliott, M. R., Gruber, F., Han, J., Chen, W., et al. (2010) · Circulation Research · doi:10.1161/circresaha.109.215715 · Cited by 573 · cited 1×
“oxidatively modified lipids in the atherosclerotic plaque, called “Mox”, has been identified [46].”
BackgroundAhsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570 · cited 1×
“2) Cytoplasmic delivery via endocytosis and lysosomal escape: Another strategy to avoid phagocytic destruction is to design particles that escape phagosomes after endocytosis but prior to fusion with the lysosome [56].”
BackgroundKrenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554 · cited 13×
“NAFLD develops due to long-term high carbohydrate or fat consumption, resulting in hepatocyte lipid accumulation and cell death.”
BackgroundInfluentialEnsan, S., Li, A., Besla, R., Degousee, N., Cosme, J., Roufaiel, M., Shikatani, E. A., El-Maklizi, M., Williams, J. W., Robins, L., et al. (2016) · Nature Immunology · doi:10.1038/ni.3343 · Cited by 372
Tumor necrosis factor-α converting enzyme
Black, R. A. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00097-8 · Cited by 346
Coats, B. R., Schoenfelt, K. Q., Barbosa-Lorenzi, V. C., Peris, E., Cui, C., Hoffman, A., Zhou, G., Fernandez, S., Zhai, L., Hall, B. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.096 · Cited by 291
Meli, R., Mattace Raso, G., & Calignano, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00177 · Cited by 137
Cited by
Macrophages in Atherosclerosis Regression
Barrett, T. J. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312802 · Cited by 628
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Hou, J., Zhang, J., Cui, P., Zhou, Y., Liu, C., Wu, X., Ji, Y., Wang, S., Cheng, B., Ye, H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135197 · Cited by 239
“Tissue-resident macrophages are the first responding immune cells to organ injury (27, 28).”
BackgroundMacrophage-based nanotherapeutic strategies in ulcerative colitis
Zhang, J., Zhao, Y., Hou, T., Zeng, H., Kalambhe, D., Wang, B., Shen, X., & Huang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.047 · Cited by 160
Fan, N., Zhang, X., Zhao, W., Zhao, J., Luo, D., Sun, Y., Li, D., Zhao, C., Wang, Y., Zhang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73890 · Cited by 104
“Macrophage polarization has recently emerged as an important therapeutic target against various metabolic diseases including insulin resistance, NAFLD and atherosclerosis [35].”
Background
Metadata
- Authors
- Peterson, K. R., Cottam, M. A., Kennedy, A. J., & Hasty, A. H.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 39
- Issue
- 6
- Pages
- 536-546
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2796005422
- Cited by
- 124
- References
- 23
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.